Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia

Atherosclerosis

Volumn 220, Issue 2, 2012, Pages 537-544

  Koh, Kwang Kon ^a   Quon, Michael J ^b   Shin, Kwen Chul ^a   Lim, Soo ^c   Lee, Yonghee ^d   Sakuma, Ichiro ^e   Lee, Kyounghoon ^a   Han, Seung Hwan ^a   Shin, Eak Kyun ^a  

^a Gachon University College of Medicine   (South Korea)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c Seoul National University Bundang Hospital   (South Korea)

^d University of Seoul   (South Korea)

^e Hokko Memorial Clinic   (Japan)

Author keywords

Fenofibrate; Hypertriglyceridemia; Insulin resistance; Omega 3 fatty acids

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; FENOFIBRATE; FIBRINOGEN; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; OMEGA 3 FATTY ACID; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; GROUPS BY AGE; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SINGLE BLIND PROCEDURE; VASODILATATION; VASOMOTOR REFLEX;

ADIPONECTIN; ANALYSIS OF VARIANCE; APOLIPOPROTEIN A-I; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FEMALE; FENOFIBRATE; FIBRINOGEN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; INFLAMMATION MEDIATORS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; REPUBLIC OF KOREA; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; VASODILATION;

EID: 84855950126     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.11.018     Document Type: Article

References (50)

1. Jun M., Foote C., Lv J., et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010, 375:1875-1884.
2. Koh K.K., Quon M.J., Rosenson R.S., Chung W.-J., Han S.H. Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates. Int J Cardiol 2008, 124:149-159.
3. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-prevenzione trial: gruppo Italiano per lo studio della sopravvivenza nell'infarto miocardico. Lancet 1999, 354:447-455.
4. Marchioli R., Barzi F., Bomba E., et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the gruppo Italiano per lo studio della sopravvivenza nell'infarto miocardico (GISSI)-prevenzione. Circulation 2002, 105:1897-1903.
5. Streppel M.T., Ocke M.C., Boshuizen H.C., Kok F.J., Kromhout D. Long-term fish consumption and n-3 fatty acid intake in relation to (sudden) coronary heart disease death: the Zutphen study. Eur Heart J 2008, 29:2024-2030.
6. Bays H.E., Tighe A.P., Sadovsky R., Davidson M.H. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther 2008, 6:391-409.
7. Mori T.A., Watts G.F., Burke V., Hilme E., Puddey I.B., Beilin L.J. Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation 2000, 102:1264-1269.
8. Stirban A., Nandrean S., Gotting C., et al. Effects of n-3 fatty acids on macro- and microvascular function in subjects with type 2 diabetes mellitus. Am J Clin Nutr 2010, 91:808-813.
9. Koh K.K. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000, 47:648-657.
10. Kim J., Montagnani M., Koh K.K., Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006, 113:1888-1904.
11. Han S.H., Quon M.J., Koh K.K. Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction. Curr Opin Lipidol 2007, 18:58-65.
12. Park H.-W., Kwon T.G., Kim K.-Y., Bae J.-H. Diabetes, insulin resistance and atherosclerosis surrogates in patients with coronary atherosclerosis. Korean Circ J 2010, 40:62-67.
13. Lim S., Despres J.-P., Koh K.K. Prevention of atherosclerosis in overweight/obese patients: in need of novel multi-targeted approaches. Circ J 2011, 75:1019-1027.
14. Han S.H., Quon M.J., Kim J.A., Koh K.K. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 2007, 49:531-538.
15. Koh K.K., Park S.M., Quon M.J. Leptin and cardiovascular disease: response to therapeutic interventions. Circulation 2008, 117:3238-3249.
16. Li S., Shin H.J., Ding E.L., van Dam R.M. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009, 302:179-188.
17. Son J.W., Koh K.K., You S.M., et al. Effects of simvastatin alone or combined with ramipril on nitric oxide bioactivity and inflammation markers in hypercholesterolemic patients. Korean Circ J 2003, 33:1053-1059.
18. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004, 110:3687-3692.
19. Koh K.K., Han S.H., Quon M.J., Ahn J.Y., Shin E.K. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 2005, 28:1419-1424.
20. Koh K.K., Quon M.J., Han S.H., Chung W.-J., Lee Y., Shin E.K. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol 2006, 108:96-100.
21. Koh K.K., Han S.H., Ahn J.Y., Chung W.-J., Lee Y., Shin E.K. Amlodipine improves endothelial function and metabolic parameters in patients with hypertension. Int J Cardiol 2009, 133:23-31.
22. Koh K.K., Quon M.J., Han S.H., Lee Y., Kim S.J., Shin E.K. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 2010, 55:1209-1216.
23. Katz A., Nambi S.S., Mather K., et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000, 85:2402-2410.
24. Muniyappa R., Lee S., Chen H., Quon M.J. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008, 294:e15-e26.
25. Ouchi N., Kihara S., Funahashi T., et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003, 107:671-674.
26. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of patients with combined hyperlipidemia. J Am Coll Cardiol 2005, 45:1649-1653.
27. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic, hypertensive patients. Diabetes Care 2006, 29:195-201.
28. Tsuchida A., Yamauchi T., Takekawa S., et al. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes 2005, 54:3358-3370.
29. Choi K.C., Ryu O.H., Lee K.W., et al. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem Biophys Res Commun 2005, 336:747-753.
30. Rosenson R.S., Wolff D.A., Huskin A.L., Helenowski I.B., Rademaker A.W. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 2007, 30:1945-1951.
31. Rosenson R.S. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. Obesity (Silver Spring) 2009, 17:504-509.
32. Han S.H., Sakuma I., Shin E.K., Koh K.K. Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. Prog Cardiovasc Dis 2009, 52:126-140.
33. Chen H., Montagnani M., Funahashi T., Shimomura I., Quon M.J. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003, 278:45021-45026.
34. Guerre-Millo M., Gervois P., Raspe E., et al. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 2000, 275:16638-16642.
35. Ginsberg H.N., Elam M.B., Lovato L.C., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Eng J Med 2010, 362:1563-1574.
36. Chew E.Y., Ambrosius W.T., Davis M.D., et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010, 363:233-244.
37. Eckel R.H. The fish oil story remains fish. Circulation 2010, 122:2110-2112.
38. Holness M.J., Smith N.D., Greenwood G.K., Sugden M.C. Acute omega-3 fatty acid enrichment selectively reverses high-saturated fat feeding-induced insulin hypersecretion but does not improve peripheral insulin resistance. Diabetes 2004, 53(Suppl.):S166-S171.
39. Svegliati-Baroni G., Candelaresi C., Saccomanno S., et al. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol 2006, 169:846-860.
40. Mishra A., Chaudhary A., Sethi S. Oxidized omega-3 fatty acids inhibit NF-kappaB activation via a PPARalpha-dependent pathway. Arterioscler Thromb Vasc Biol 2004, 24:1621-1627.
41. Shapiro H., Bruck R. Omega-3 may indirectly reduce hepatocyte triglycerides through modulation of hyperinsulinemia, cytokines and adipocytokines. Am J Cardiol 2007, 99:146.
42. Grundt H., Nilsen D.W., Hetland O., et al. Improvement of serum lipids and blood pressure during intervention with n-3 fatty acids was not associated with changes in insulin levels in subjects with combined hyperlipidaemia. J Intern Med 1995, 237:249-259.
43. Durrington P.N., Bhatnagar D., Mackness M.I., et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 2001, 85:544-548.
44. Yokoyama M., Origasa H., Matsuzaki M., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007, 369:1090-1098.
45. Tavazzi L., Maggioni A.P., Marchioli R., et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1223-1230. Gissi-HF Investigators.
46. Rauch B., Schiele R., Schneider S., et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline adjusted therapy after myocardial infarction. Circulation 2010, 122:2152-2159.
47. Kromhout D., Giltay E., Geleijnse J.M. N-3 Fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010, 363:2015-2026. Alpha Omega Trial Group.
48. Mather K.J., Hunt A.E., Steinberg H.O., et al. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab 2001, 86:5457-5464.
49. Katsuki A., Sumida Y., Gabazza E.C., et al. QUICKI is useful for following improvements in insulin sensitivity after therapy in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2002, 87:2906-2908.
50. Hanley A.J., Williams K., Gonzalez C., et al. Prediction of type 2 diabetes using simple measures of insulin resistance: combined results from the San Antonio heart study, the Mexico City diabetes study, and the insulin resistance atherosclerosis study. Diabetes 2003, 52:463-469.